Cost Management Insights: SG&A Expenses for Viatris Inc. and Evotec SE

Navigating Cost Management: A Tale of Two Companies

In the ever-evolving landscape of pharmaceuticals, effective cost management is crucial. Viatris Inc. and Evotec SE, two giants in the industry, have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses over the past decade.

Viatris Inc.: A Steady Climb

From 2014 to 2023, Viatris Inc. has seen a consistent increase in SG&A expenses, peaking at approximately $4.65 billion in 2023. This represents a staggering 210% increase from 2014, reflecting the company's aggressive expansion and investment in operational capabilities.

Evotec SE: A Strategic Approach

Conversely, Evotec SE's SG&A expenses have grown more modestly, with a 840% increase over the same period, reaching around $169 million in 2023. This indicates a more strategic and controlled approach to cost management, focusing on sustainable growth.

These insights highlight the diverse strategies employed by leading pharmaceutical companies in managing operational costs, offering valuable lessons for industry stakeholders.